Skip to content
Immunai logo — Mapping the Immune System with AI to Improve Health

Immunai

Mapping the Immune System with AI to Improve Health

Founded 2019 United States New York, United States 171 employees Series B Total: $300.50M Biotechnology, Pharmaceutical

General Information

Company Name Immunai
Founded Year 2019
Location United States New York, United States
Employees 171
Industries Biotechnology, Pharmaceutical
Funding Stage Series B
Business Model B2B, Platform, SaaS
Revenue Model Subscription, Service Fee, Project Based
Social

BounceWatch is an independent company data service, not affiliated with Immunai. To contact Immunai, visit immunai.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Immunai compare?

A PDF of Immunai and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Immunai soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Immunai

Immunai, founded in 2019, is a United States-based startup that is revolutionizing the Biotechnology and Pharmaceutical industries with its innovative approach. The company's slogan, "Mapping the Immune System with AI to Improve Health," reflects its mission to map and decode the immune system using single-cell biology and artificial intelligence. This approach aims to unleash new therapeutic discoveries, speed up drug development, and enhance patient outcomes.

Immunai's ability to integrate cutting-edge technology positions it as a significant player in the realm of precision medicine. Their most recent major funding event, a $215.00M Series B investment on 01 October 2021, underscores investor confidence in their model. Key investors in this round included 8VC, Alexandria Venture Investments, Koch Disruptive Technologies, Talos, and Piedmont Healthcare. This substantial backing not only provides financial runway but also strategic support as Immunai continues to scale its operations and impact in the healthcare sector.

Business keywords: immune system mapping, single-cell genomics, biotech, therapeutic discoveries, drug development, patient outcomes, biomarker discovery, high-resolution profiling, immune profiling, cellular response analysis, cancer research, genomic technologies, high-dimensional statistics, single-cell biology

Services & Products

Target Discovery
Preclinical Evaluation
Clinical Trial Optimization
Data Generation
Data Augmentation
Compute and Validate Therapeutic Insights
Recommendation Engine

Target Customers

biopharmaceutical companies research institutions pharma companies

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $215.00M 5
8VC, Alexandria Venture Investments +3
01 Oct 2021
Series A $60.00M 6
Viola Ventures, Catalio Capital Management +4
01 Feb 2021
Seed $20.00M 2
Viola Ventures, TLV Partners
01 May 2020
Angel Undisclosed -
01 Dec 2019
Spinout $5.50M 1
TLV Partners
01 Feb 2019

Immunai Alternatives & Competitors

View All Alternatives
Immunai vs
Cellarity
Cellarity United States

Rewriting the rules of drug creation

Series C
61 employees
Biotechnology, Life Sciences
Immunai vs
Enable Medicine
Enable Medicine United States

Spatial and multimodal insights powered by AI for your next therapeutic breakthrough.

Acquired
15 employees
Biotechnology, Pharmaceutical
Immunai vs
Parallel Bio
Parallel Bio United States

Using the immune system to cure disease.

Series A
27 employees
Biotechnology, Health and Wellness

FAQ About Immunai

Mapping the Immune System with AI to Improve Health
Immunai was founded in 2019.
Immunai is headquartered in New York, United States.
Immunai operates in Biotechnology and Pharmaceutical. Its work centres on immune system mapping, single-cell genomics, biotech and therapeutic discoveries. Its customers include biopharmaceutical companies, research institutions and pharma companies.
Immunai has a B2B, Platform and SaaS business model. Its revenue comes from Subscription, Service Fee and Project Based.
Immunai has approximately 171 employees.
Immunai has completed 5 funding rounds, raising a total of $300.50M. The latest funding stage is Series B.
Immunai offers: Target Discovery, Preclinical Evaluation, Clinical Trial Optimization, Data Generation, Data Augmentation, Compute and Validate Therapeutic Insights, Recommendation Engine.
Top alternatives and competitors to Immunai include Cellarity, Enable Medicine, Parallel Bio, Relation, KSQ Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Immunai and Cellarity are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Immunai, https://www.bouncewatch.com/company/immunai, updated 6 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout